Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

• Published in: Circulation (New York, N.Y.) Vol. 137; no. 4; pp. 338 - 350
• Main Authors: Bonaca, Marc P., Nault, Patrice, Giugliano, Robert P., Keech, Anthony C., Pineda, Armando Lira, Kanevsky, Estella, Kuder, Julia, Murphy, Sabina A., Jukema, J. Wouter, Lewis, Basil S., Tokgozoglu, Lale, Somaratne, Ransi, Sever, Peter S., Pedersen, Terje R., Sabatine, Marc S.
• Format: Journal Article
• Language: English
• Published: United States by the American College of Cardiology Foundation and the American Heart Association, Inc 23.01.2018
• Subjects: Aged; Amputation; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents - adverse effects; Anticholesteremic Agents - therapeutic use; Biomarkers - blood; Cholesterol, LDL - blood; Down-Regulation; Dyslipidemias - blood; Dyslipidemias - diagnosis; Dyslipidemias - drug therapy; Dyslipidemias - mortality; Female; Humans; Limb Salvage; Male; Middle Aged; Peripheral Arterial Disease - blood; Peripheral Arterial Disease - diagnosis; Peripheral Arterial Disease - mortality; Peripheral Arterial Disease - therapy; Proprotein Convertase 9 - antagonists & inhibitors; Proprotein Convertase 9 - metabolism; Risk Factors; Serine Proteinase Inhibitors - adverse effects; Serine Proteinase Inhibitors - therapeutic use; Time Factors; Treatment Outcome; atherosclerosis; amputation; cholesterol, LDL; evolocumab; peripheral arterial disease; PCSK9 protein, human; intermittent claudication

BACKGROUND:The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). We investigated the ef...